2cureX Aktie - Dagens Industri

20 maj 2022, 08:45

Realtid

Över 1100 aktier i realtid

Du som prenumerant får börsen i realtid, alla svenska aktiekurser uppdateras direkt på din skärm när avslut sker. Om du inte prenumererar hämtas all börsdata med 15 min fördröjning

Prenumerera Logga in

2cureX

11,44

SEK

0,00SEK0,00%

Högst

Volym

Lägst

Börsvärde* MSEK

201

Nu kan du favoritmärka aktier.
Till dina favoriter

OMX Stockholm PI
OMX Stockholm 30
S&P 500
FTSE 100
Dow Jones
Dow Jones Europe Index
Dow Jones China Broad Market Index
Nikkei

-6,84%

-16,13%

-24,14%

-31,90%

-46,29%

-29,38%

Nyckeltal

Nyckeltalen är baserade på senaste rapporten

Ticker

2CUREX

Antal aktier

17 602 916

Börslista

First North

Sektor

Hälsovård

P/s-tal

P/e-tal

-11,32

P/eget kapital

2,53

Eget kapital/aktie

4,53

Omsättning/aktie

0,00

Vinst/aktie

-1,15

Utdelning/aktie

0,00

Direktavkastning

0,00

Fler nyckeltal

Nyheter om bolaget

Nyheter Telegram Pressmeddelanden

Ingen data tillgänglig.

Tisdag 8 mars

TRADING DIREKT: "RIKSBANKEN KAN HÖJA RÄNTAN REDAN SEPTEMBER"

Publicerad: 2022-03-08 (Direkt-SE)

Torsdag 16 december

2CUREX: SPANSKT SJUKHUS GÅR MED I IGNITE-PROGRAMMET

Publicerad: 2021-12-16 (Direkt-SE)

Måndag 13 december

2CUREX: NÅR MÅL EFTER TECKNANDE AV DISTRIBUTIONSAVTAL

Publicerad: 2021-12-13 (Direkt-SE)

Torsdag 25 november

2CUREX: RESULTAT EFTER FINANSIELLA POSTER -6,4 MLN KR 3 KV

Publicerad: 2021-11-25 (Direkt-SE)

Tisdag 12 oktober

2CUREX: MÅL 30 SJUKHUS SKA ANVÄNDA INDITREAT 2022

Publicerad: 2021-10-12 (Direkt-SE)

Torsdag 26 augusti

2CUREX:RES EFTER FINANSIELLA POSTER VAR -8,8 MLN KR 2 KV

Publicerad: 2021-08-26 (Direkt-SE)

Fredag 4 juni

2CUREX: REDEYE HÖJER RIKTVÄRDE I BASSCENARIO TILL 31 KR (23)

Publicerad: 2021-06-04 (Direkt-SE)

Fredag 28 maj

2CUREX: RESULTAT EFTER SKATT VAR -1,8 MLN KR (-1,1) 1 KV (OMS)

Publicerad: 2021-05-28 (Direkt-SE)

Torsdag 27 maj

2CUREX: RESULTAT EFTER SKATT VAR -1,8 MLN KR (-1,1) 1 KV

Publicerad: 2021-05-27 (Direkt-SE)

Fler telegram

Tisdag 17 maj

Three IndiTreat® posters have been accepted at ESMO-GI 2022

Publicerad: Tisdag 08:45 (MFN)

Torsdag 12 maj

2cureX AB nominerar Dr. Michael Schaefer till styrelsen

Publicerad: 2022-05-12 (MFN)

2cureX AB nominates Dr. Michael Schaefer to the Board of Directors

Publicerad: 2022-05-12 (MFN)

Onsdag 11 maj

IGNITE update - Eight hospitals have been enrolled in the program

Publicerad: 2022-05-11 (MFN)

Måndag 9 maj

2cureX presents IndiTreat® clinical results at the Society for Functional Precision Medicine

Publicerad: 2022-05-09 (MFN)

Fredag 6 maj

2cureX appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company´s share

Publicerad: 2022-05-06 (MFN)

2cureX utser Sedermera Corporate Finance AB till likviditetsgarant för bolagets aktie

Publicerad: 2022-05-06 (MFN)

Torsdag 5 maj

Redeye research interview with 2cureX CEO, Fernando Andreu

Publicerad: 2022-05-05 (MFN)

Tisdag 3 maj

2cureX publishes the annual report for the fiscal year 2021

Publicerad: 2022-05-03 (MFN)

2cureX offentliggör årsredovisning för räkenskapsåret 2021

Publicerad: 2022-05-03 (MFN)

Fredag 29 april

Rättelse: Korrektion till “Kallelse till årsstämma i 2cureX AB” utfärdad den 21 april 2022

Publicerad: 2022-04-29 (MFN)

Fredag 22 april

Korrektion till “Kallelse till årsstämma i 2cureX AB” utfärdad den 21 april 2022

Publicerad: 2022-04-22 (MFN)

Correction of “Notice of annual general meeting of 2cureX AB (publ)” issued on 21st April 2022

Publicerad: 2022-04-22 (MFN)

Torsdag 21 april

Notice of annual general meeting of 2cureX AB (publ)

Publicerad: 2022-04-21 (MFN)

Kallelse till årsstämma i 2cureX AB

Publicerad: 2022-04-21 (MFN)

Manuel Fernández joins 2cureX as Director of Quality Assurance and Regulatory Affairs.

Publicerad: 2022-04-21 (MFN)

Torsdag 14 april

Chairman of the 2cureX Board exercises all warrants within the framework of the 2018 incentive program

Publicerad: 2022-04-14 (MFN)

Tisdag 15 mars

Mangold Fondkommission AB published an updated Analyst Report on 2cureX

Publicerad: 2022-03-15 (MFN)

2cureX - Krattat för lansering - Mangold Insight Analys

Publicerad: 2022-03-15 (Cision)

Måndag 14 mars

2cureX launches IndiTreat® mCRC Explore and completes portfolio rollout plan for 2022

Publicerad: 2022-03-14 (MFN)

Torsdag 24 februari

2cureX offentliggör delårsrapport för det fjärda kvartalen och alla tolv månader 2021

Publicerad: 2022-02-24 (MFN)

2cureX publishes interim report for the fourth quarter and all 12 months of 2021

Publicerad: 2022-02-24 (MFN)

Onsdag 23 februari

2cureX holds a virtual live-session on the 25th of February 2022 to present and discuss the Interim report for the fourth quarter of 2021.

Publicerad: 2022-02-23 (MFN)

2cureX reorganizes to an even stronger distributor focus

Publicerad: 2022-02-23 (MFN)

Fredag 21 januari

New Institutional shareholder

Publicerad: 2022-01-21 (MFN)

Tisdag 11 januari

IndiTreat® to be distributed in Czech Republic and Slovakia through Promedica

Publicerad: 2022-01-11 (MFN)

Onsdag 5 januari

IndiTreat® to be distributed in Poland by Perlan Technologies

Publicerad: 2022-01-05 (MFN)

Onsdag 22 december

First IndiTreat® order received from Labormed, Slovenia

Publicerad: 2021-12-22 (MFN)

Torsdag 16 december

First hospital joins the IndiTreat® Evaluation Program IGNITE

Publicerad: 2021-12-16 (MFN)

Tisdag 14 december

2cureX launches IndiTreat® mCRC Start test to guide 1st line treatment

Publicerad: 2021-12-14 (MFN)

Måndag 13 december

2cureX reaches the goals for the 2021 rollout plan

Publicerad: 2021-12-13 (MFN)

Torsdag 9 december

2cureX signs yet another distribution agreement – this time with Omnigen Medical Products in Turkey

Publicerad: 2021-12-09 (MFN)

Måndag 29 november

EU publishes an article about the successful finalization of 2cureX’s MicroCaT project.

Publicerad: 2021-11-29 (MFN)

Torsdag 25 november

2cureX offentliggör delårsrapport för det tredje kvartalet och första nio månader 2021

Publicerad: 2021-11-25 (MFN)

2cureX publishes interim report for the third quarter and first nine months of 2021

Publicerad: 2021-11-25 (MFN)

Onsdag 24 november

2cureX expands its Clinical Advisory Board with Professor Andrew Beggs, Queen Elizabeth Hospital Birmingham, UK

Publicerad: 2021-11-24 (MFN)

Tisdag 23 november

2cureX holds a virtual live-session on the 26th of November 2021 to present and discuss the Interim report for the third quarter of 2021.

Publicerad: 2021-11-23 (MFN)

Fredag 29 oktober

Mangold Fondkommission AB published an updated Analyst Report on 2cureX

Publicerad: 2021-10-29 (MFN)

2cureX - Banbrytande cancerbehandlingstest rullas ut - Mangold Insight Analys

Publicerad: 2021-10-29 (Cision)

Fredag 15 oktober

2cureX successfully completed the EU-project MicroCaT and received the final financial tranche of a 3,0 MEUR grant.

Publicerad: 2021-10-15 (MFN)

Tisdag 12 oktober

2cureX provides commercial goals for 2022 at Live Strategy Update on the 12th of October 2021.

Publicerad: 2021-10-12 (MFN)

Fredag 8 oktober

2cureX provides a Live Strategy Update on the company’s product portfolio and commercialization strategy on the 12th of October 2021.

Publicerad: 2021-10-08 (MFN)

Tisdag 5 oktober

2cureX signs distribution agreement with Labormed in Slovenia

Publicerad: 2021-10-05 (MFN)

Tisdag 28 september

Specialized diagnostic solutions leader Werfen, to distribute 2cureX products in Spain

Publicerad: 2021-09-28 (MFN)

Torsdag 26 augusti

2cureX offentliggör delårsrapport för det andra kvartalet och första halvåret 2021

Publicerad: 2021-08-26 (Cision)

2cureX publishes interim report for the second quarter and first half of 2021

Publicerad: 2021-08-26 (Cision)

Fredag 20 augusti

2cureX: New development of the IndiTreat® technology allows prediction of response to anti-angiogenic drugs in colorectal cancer.

Publicerad: 2021-08-20 (Cision)

Onsdag 18 augusti

Upcoming events in the fall from 2cureX

Publicerad: 2021-08-18 (Cision)

Torsdag 29 juli

2cureX appoints two internationally highly recognized oncologists as Clinical Advisors

Publicerad: 2021-07-29 (Cision)

Måndag 19 juli

2cureX receives important ISO 13485:2016 certification

Publicerad: 2021-07-19 (Cision)

Tisdag 22 juni

2cureX appoints 2 new VPs for its Commercial Operations

Publicerad: 2021-06-22 (Cision)

Onsdag 9 juni

2cureX Newsletter #9

Publicerad: 2021-06-09 (Cision)

Måndag 7 juni

2cureX: ASCO Update - New Treatment strategy prolongs progression free survival in colorectal cancer patients

Publicerad: 2021-06-07 (Cision)

Fredag 4 juni

REDEYE releases an updated 2cureX Equity Research Report

Publicerad: 2021-06-04 (Cision)

Redeye: 2cureX - IndiTreat market launch imminent

Publicerad: 2021-06-04 (MFN)

Tisdag 1 juni

2cureX: Management exercise all warrants within the framework of the 2018 incentive program

Publicerad: 2021-06-01 (Cision)

Torsdag 27 maj

2cureX offentliggör delårsrapport för det första kvartalet 2021

Publicerad: 2021-05-27 (Cision)

2cureX publishes interim report for the first quarter of 2021

Publicerad: 2021-05-27 (Cision)

Communiqué from the Annual General Meeting of 2cureX AB

Publicerad: 2021-05-27 (Cision)

Kommuniké från årsstämma i 2cureX AB

Publicerad: 2021-05-27 (Cision)

Måndag 24 maj

BioStock: Nya data från 2cureX IndiTreat på ASCO

Publicerad: 2021-05-24 (Cision)

Fler pressmeddelanden

OMXSPI

S&P 500

FTSE 100

DAX 30

NIKKEI

DOW JONES

2cureX • Aktiekurs

Över 1100 aktier i realtid

2cureX

Högst

Volym

Lägst

Börsvärde* MSEK

Nyckeltal

Ticker

Antal aktier

Börslista

Sektor

P/s-tal

P/e-tal

P/eget kapital

Eget kapital/aktie

Omsättning/aktie

Vinst/aktie

Utdelning/aktie

Direktavkastning

Nyheter om bolaget

TRADING DIREKT: "RIKSBANKEN KAN HÖJA RÄNTAN REDAN SEPTEMBER"

2CUREX: SPANSKT SJUKHUS GÅR MED I IGNITE-PROGRAMMET

2CUREX: NÅR MÅL EFTER TECKNANDE AV DISTRIBUTIONSAVTAL

2CUREX: RESULTAT EFTER FINANSIELLA POSTER -6,4 MLN KR 3 KV

2CUREX: MÅL 30 SJUKHUS SKA ANVÄNDA INDITREAT 2022

2CUREX:RES EFTER FINANSIELLA POSTER VAR -8,8 MLN KR 2 KV

2CUREX: REDEYE HÖJER RIKTVÄRDE I BASSCENARIO TILL 31 KR (23)

2CUREX: RESULTAT EFTER SKATT VAR -1,8 MLN KR (-1,1) 1 KV (OMS)

2CUREX: RESULTAT EFTER SKATT VAR -1,8 MLN KR (-1,1) 1 KV

Three IndiTreat® posters have been accepted at ESMO-GI 2022

2cureX AB nominerar Dr. Michael Schaefer till styrelsen

2cureX AB nominates Dr. Michael Schaefer to the Board of Directors

IGNITE update - Eight hospitals have been enrolled in the program

2cureX presents IndiTreat® clinical results at the Society for Functional Precision Medicine

2cureX appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company´s share

2cureX utser Sedermera Corporate Finance AB till likviditetsgarant för bolagets aktie

Redeye research interview with 2cureX CEO, Fernando Andreu

2cureX publishes the annual report for the fiscal year 2021

2cureX offentliggör årsredovisning för räkenskapsåret 2021

Rättelse: Korrektion till “Kallelse till årsstämma i 2cureX AB” utfärdad den 21 april 2022

Korrektion till “Kallelse till årsstämma i 2cureX AB” utfärdad den 21 april 2022

Correction of “Notice of annual general meeting of 2cureX AB (publ)” issued on 21st April 2022

Notice of annual general meeting of 2cureX AB (publ)

Kallelse till årsstämma i 2cureX AB

Manuel Fernández joins 2cureX as Director of Quality Assurance and Regulatory Affairs.

Chairman of the 2cureX Board exercises all warrants within the framework of the 2018 incentive program

Mangold Fondkommission AB published an updated Analyst Report on 2cureX

2cureX - Krattat för lansering - Mangold Insight Analys

2cureX launches IndiTreat® mCRC Explore and completes portfolio rollout plan for 2022

2cureX offentliggör delårsrapport för det fjärda kvartalen och alla tolv månader 2021

2cureX publishes interim report for the fourth quarter and all 12 months of 2021

2cureX holds a virtual live-session on the 25th of February 2022 to present and discuss the Interim report for the fourth quarter of 2021.

2cureX reorganizes to an even stronger distributor focus

New Institutional shareholder

IndiTreat® to be distributed in Czech Republic and Slovakia through Promedica

IndiTreat® to be distributed in Poland by Perlan Technologies

First IndiTreat® order received from Labormed, Slovenia

First hospital joins the IndiTreat® Evaluation Program IGNITE

2cureX launches IndiTreat® mCRC Start test to guide 1st line treatment

2cureX reaches the goals for the 2021 rollout plan

2cureX signs yet another distribution agreement – this time with Omnigen Medical Products in Turkey

EU publishes an article about the successful finalization of 2cureX’s MicroCaT project.

2cureX offentliggör delårsrapport för det tredje kvartalet och första nio månader 2021

2cureX publishes interim report for the third quarter and first nine months of 2021

2cureX expands its Clinical Advisory Board with Professor Andrew Beggs, Queen Elizabeth Hospital Birmingham, UK

2cureX holds a virtual live-session on the 26th of November 2021 to present and discuss the Interim report for the third quarter of 2021.

Mangold Fondkommission AB published an updated Analyst Report on 2cureX

2cureX - Banbrytande cancerbehandlingstest rullas ut - Mangold Insight Analys

2cureX successfully completed the EU-project MicroCaT and received the final financial tranche of a 3,0 MEUR grant.

2cureX provides commercial goals for 2022 at Live Strategy Update on the 12th of October 2021.

2cureX provides a Live Strategy Update on the company’s product portfolio and commercialization strategy on the 12th of October 2021.

2cureX signs distribution agreement with Labormed in Slovenia

Specialized diagnostic solutions leader Werfen, to distribute 2cureX products in Spain